Myriad Genetics, Inc. (MYGN)
After hours:
| Previous Close | 27.85 |
| Open | 28.27 |
| Bid | 27.61 x 600 |
| Ask | 27.67 x 300 |
| Day's Range | 27.21 - 28.27 |
| 52 Week Range | 13.82 - 28.90 |
| Volume | |
| Avg. Volume | 865,270 |
| Market Cap | 2.503B |
| Beta (5Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.80 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.83 |
ZacksINCY or MYGN: Which Is the Better Value Stock Right Now?
INCY vs. MYGN: Which Stock Is the Better Value Option?
GlobeNewswireWhat We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast CancerSALT LAKE CITY, July 17, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from its nationwide Cancer Risk Survey: Breast Cancer Edition, which revealed that a majority (63%) of women do not know that there is an increased risk of breast cancer for women with dense breast
ZacksMyriad Genetics (MYGN) Expands in MRD Testing With New Collab
Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.
